Gilead Sciences, Inc. (GILD) on Decifer

Why it ranks here

• Sales are growing about 7% a year, faster than 28 in 100 companies we measure.
• It costs about 6 times its yearly sales; the middle of its industry is 6. Cheaper than 46 in 100 companies we measure, against their own industries.

The current read

The evidence on GILD lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• Next-Gen Genetic & RNA/Antibody Therapeutics: Platform breakthroughs in RNA interference, redosable gene therapy and antibody engineering are converting once-undruggable and orphan targets into commercial therapies.

Read the full GILD research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.